Whitehawk Therapeutics (NASDAQ:WHWK) Coverage Initiated by Analysts at Jones Trading

Jones Trading began coverage on shares of Whitehawk Therapeutics (NASDAQ:WHWK) in a report issued on Monday,Benzinga reports. The brokerage issued a buy rating and a $7.00 price objective on the stock.

Several other equities analysts also recently commented on the stock. Weiss Ratings reissued a “sell (e+)” rating on shares of Whitehawk Therapeutics in a research report on Monday, December 15th. Wall Street Zen downgraded Whitehawk Therapeutics to a “strong sell” rating in a research note on Saturday, November 1st. Finally, Zacks Research upgraded Whitehawk Therapeutics from a “strong sell” rating to a “hold” rating in a report on Tuesday, October 7th. One analyst has rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Whitehawk Therapeutics presently has a consensus rating of “Hold” and a consensus target price of $7.00.

Whitehawk Therapeutics Stock Performance

Shares of WHWK opened at $2.49 on Monday. The company has a market capitalization of $117.35 million, a price-to-earnings ratio of 17.79 and a beta of 0.38. The company’s 50 day simple moving average is $2.30. Whitehawk Therapeutics has a twelve month low of $1.39 and a twelve month high of $3.81.

Whitehawk Therapeutics (NASDAQ:WHWK) last announced its quarterly earnings results on Thursday, November 6th. The company reported ($0.26) EPS for the quarter, topping the consensus estimate of ($0.51) by $0.25. Whitehawk Therapeutics had a net margin of 99.42% and a negative return on equity of 68.32%.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the business. ABG Innovation Capital Partners III GP Ltd bought a new stake in shares of Whitehawk Therapeutics in the third quarter valued at approximately $51,000. Dimensional Fund Advisors LP acquired a new position in Whitehawk Therapeutics during the 3rd quarter valued at $84,000. Squarepoint Ops LLC bought a new stake in Whitehawk Therapeutics in the 3rd quarter valued at $159,000. Citadel Advisors LLC bought a new stake in Whitehawk Therapeutics in the 3rd quarter valued at $266,000. Finally, Bridgeway Capital Management LLC bought a new position in shares of Whitehawk Therapeutics during the 3rd quarter worth about $409,000. 52.08% of the stock is owned by institutional investors.

Whitehawk Therapeutics Company Profile

Aadi Bioscience, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. The company was incorporated in 2007 and is headquartered in Pacific Palisades, California.